Lilly to Acquire Merida for $2.875B in Autoimmune Drug Push

Eli Lilly and Company has entered into a definitive agreement to acquire Merida Biosciences, a biotechnology company focused on developing precision treatments for serious autoimmune and allergic diseases. The transaction, valued at up to $2.875 billion in cash, including an upfront payment and contingent milestone payments, is expected to strengthen Lilly’s immunology pipeline and broaden its capabilities in antibody-driven diseases.

Merida is developing a new class of biologic therapies designed to selectively eliminate pathogenic autoantibodies, which are responsible for triggering or worsening several immune-mediated disorders. Unlike conventional treatments that broadly suppress immune activity, Merida’s technology aims to directly remove disease-causing antibodies while preserving normal immune function.

The company’s leading candidate, MER511, is currently in Phase 1 clinical development for Graves’ disease and thyroid eye disease (TED). Both conditions are associated with thyroid-stimulating immunoglobulins, a type of autoantibody that activates the thyroid-stimulating hormone receptor. Graves’ disease affects around 3 million people in the United States, while approximately 25% to 40% of affected patients may subsequently develop TED.

TED can result in significant pain, facial changes and, in severe cases, vision impairment. Although approved therapies are available for Graves’ disease and TED, Merida’s approach is designed to directly address the underlying pathogenic autoantibodies.

Beyond MER511, Merida is developing MER769, a preclinical program targeting food allergies, asthma and chronic spontaneous urticaria. The candidate is designed to address diseases associated with the antibody responsible for initiating allergic reactions. Merida also has earlier-stage programs targeting immune-mediated kidney diseases, including membranous nephropathy.

Lilly executives said Merida’s technology could potentially transform treatment for multiple antibody-driven diseases by addressing their biological causes rather than only managing downstream symptoms. The companies also highlighted initial Phase 1 data for MER511, which they said support the potential for improved efficacy and safety.

Merida CEO Adam Townsend said the company was founded to develop therapies that directly target antibodies driving autoimmune and allergic diseases. He added that joining Lilly would provide the financial resources and development capabilities needed to advance the technology toward patients.

The acquisition remains subject to customary closing conditions, including regulatory approvals. Lilly expects the transaction to close in the fourth quarter of 2026. Following completion, Lilly will incorporate the transaction into its financial reporting and guidance in accordance with GAAP.

Product Impact & Chemical Commodity Price Impact

The acquisition is expected to have a positive long-term impact on Merida’s drug-development platform and Lilly’s immunology portfolio, providing greater funding, clinical expertise and commercialization capabilities. MER511 and other precision biologics could benefit from accelerated development, although commercial impact will depend on clinical results and regulatory approvals. For chemical commodities tracked by ChemAnalyst, the immediate pricing impact should be limited and largely neutral, as the transaction does not directly alter large-scale chemical production or feedstock demand. Over the longer term, successful development and commercialization could modestly increase demand for pharmaceutical-grade intermediates, specialty chemicals, excipients and biologics manufacturing materials, offering slight upside to selected downstream chemical markets.